News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
598,442 Results
Type
Article (40757)
Company Profile (100)
Press Release (557573)
Multimedia
Podcasts (158)
Webinars (24)
Section
Business (170990)
Career Advice (2055)
Deals (25552)
Drug Delivery (125)
Drug Development (71550)
Employer Resources (126)
FDA (14686)
Job Trends (12304)
News (287812)
Policy (26750)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2542)
Academic (2)
Accelerated approval (33)
Adcomms (23)
Allergies (132)
Alliances (44907)
ALS (168)
Alzheimer's disease (1560)
Antibody-drug conjugate (ADC) (324)
Approvals (14962)
Artificial intelligence (548)
Autoimmune disease (164)
Automation (40)
Bankruptcy (214)
Best Places to Work (9921)
BIOSECURE Act (22)
Biosimilars (167)
Biotechnology (71)
Bladder cancer (159)
Brain cancer (58)
Breast cancer (636)
Cancer (4769)
Cardiovascular disease (402)
Career advice (1744)
Career pathing (38)
CAR-T (277)
CDC (53)
Celiac Disease (1)
Cell therapy (755)
Cervical cancer (33)
Clinical research (61633)
Collaboration (1787)
Company closure (3)
Compensation (711)
Complete response letters (56)
COVID-19 (2398)
CRISPR (88)
C-suite (819)
Cystic fibrosis (129)
Data (6222)
Decentralized trials (2)
Denatured (49)
Depression (123)
Diabetes (503)
Diagnostics (5645)
Digital health (46)
Diversity (10)
Diversity, equity & inclusion (40)
Drug discovery (270)
Drug pricing (190)
Drug shortages (32)
Duchenne muscular dystrophy (218)
Earnings (71455)
Editorial (65)
Employer branding (16)
Employer resources (116)
Events (93040)
Executive appointments (939)
FDA (17710)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (8)
Frontotemporal dementia (22)
Funding (1412)
Gene editing (187)
Generative AI (55)
Gene therapy (592)
GLP-1 (1058)
Government (3983)
Grass and pollen (6)
Guidances (366)
Healthcare (16582)
HIV (65)
Huntington's disease (42)
IgA nephropathy (77)
Immunology and inflammation (221)
Immuno-oncology (66)
Indications (119)
Infectious disease (2660)
Inflammatory bowel disease (192)
Inflation Reduction Act (15)
Influenza (112)
Intellectual property (233)
Interviews (374)
IPO (11648)
IRA (52)
Job creations (2727)
Job search strategy (1454)
JPM (63)
Kidney cancer (12)
Labor market (68)
Layoffs (439)
Leadership (36)
Legal (6144)
Liver cancer (87)
Longevity (15)
Lung cancer (648)
Lymphoma (375)
Machine learning (36)
Management (42)
Manufacturing (774)
MASH (170)
Medical device (11195)
Medtech (11244)
Mergers & acquisitions (14900)
Metabolic disorders (1336)
mRNA (145)
Multiple sclerosis (157)
NASH (17)
Neurodegenerative disease (314)
Neuropsychiatric disorders (82)
Neuroscience (2755)
Neurotech (1)
NextGen: Class of 2026 (5610)
Non-profit (4226)
Now hiring (51)
Obesity (653)
Opinion (279)
Ovarian cancer (157)
Pain (188)
Pancreatic cancer (214)
Parkinson's disease (279)
Partnered (28)
Patents (457)
Patient recruitment (502)
Peanut (49)
People (50908)
Pharmaceutical (29)
Pharmacy benefit managers (23)
Phase 1 (19051)
Phase 2 (26853)
Phase 3 (20637)
Pipeline (5503)
Policy (306)
Postmarket research (2459)
Preclinical (8059)
Press Release (69)
Prostate cancer (251)
Psychedelics (42)
Radiopharmaceuticals (253)
Rare diseases (817)
Real estate (5151)
Recruiting (51)
Regulatory (20835)
Reports (38)
Research institute (2321)
Resumes & cover letters (314)
Rett syndrome (30)
RNA editing (13)
RSV (78)
Schizophrenia (139)
Series A (245)
Series B (177)
Service/supplier (6)
Sickle cell disease (96)
Special edition (21)
Spinal muscular atrophy (137)
Sponsored (38)
Startups (2868)
State (1)
Stomach cancer (14)
Supply chain (104)
Tariffs (80)
The Weekly (107)
Vaccines (977)
Venture capital (81)
Weight loss (459)
Women's health (84)
Worklife (19)
Date
Today (109)
Last 7 days (805)
Last 30 days (2601)
Last 365 days (27663)
2026 (4477)
2025 (27890)
2024 (30524)
2023 (33780)
2022 (44102)
2021 (46931)
2020 (45346)
2019 (39807)
2018 (29971)
2017 (27392)
2016 (26658)
2015 (30687)
2014 (24820)
2013 (21375)
2012 (22114)
2011 (22680)
2010 (21045)
Location
Africa (740)
Alabama (88)
Alaska (6)
Arizona (218)
Arkansas (12)
Asia (39885)
Australia (5466)
California (10338)
Canada (2805)
China (1209)
Colorado (435)
Connecticut (470)
Delaware (335)
Europe (79795)
Florida (1464)
Georgia (335)
Hawaii (3)
Idaho (42)
Illinois (815)
India (73)
Indiana (470)
Iowa (22)
Japan (426)
Kansas (105)
Kentucky (38)
Louisiana (23)
Maine (41)
Maryland (1257)
Massachusetts (7534)
Michigan (306)
Minnesota (510)
Mississippi (6)
Missouri (103)
Montana (31)
Nebraska (24)
Nevada (111)
New Hampshire (61)
New Jersey (2889)
New Mexico (27)
New York (2790)
North Carolina (1316)
North Dakota (10)
Northern California (5026)
Ohio (300)
Oklahoma (21)
Oregon (36)
Pennsylvania (1995)
Puerto Rico (18)
Rhode Island (49)
South America (1030)
South Carolina (56)
South Dakota (1)
Southern California (4099)
Tennessee (168)
Texas (1599)
United States (36687)
Utah (309)
Vermont (1)
Virginia (244)
Washington D.C. (78)
Washington State (830)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
598,442 Results for "novo nordisk china r and d center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
February 24, 2026
·
5 min read
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
A lawsuit and FDA warning ensued after Hims & Hers launched a compounded version of Novo Nordisk’s new obesity pill, more Big Pharma report earnings—including from weight loss rivals Novo and Eli Lilly—and the gene therapy space sees another rejection.
February 11, 2026
·
1 min read
·
Jef Akst
Press Releases
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S - February 20, 2026
February 20, 2026
·
2 min read
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off.
February 23, 2026
·
4 min read
·
Annalee Armstrong
Events
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli Lilly and Novo Nordisk providing supply chain, regulatory and pricing updates.
January 13, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
January 1, 2026
·
2 min read
Obesity
Novo Nordisk Files Combo Obesity Drug CagriSema For FDA Approval
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
December 18, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid
Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk’s unsolicited bid to acquire obesity biotech Metsera.
November 3, 2025
·
4 min read
·
Tristan Manalac
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly’s orforglipron bested Novo’s oral semaglutide in blood sugar control and weight reduction—albeit with a few extra discontinuations as compared to its rival.
February 26, 2026
·
2 min read
·
Annalee Armstrong
Earnings
Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
February 3, 2026
·
2 min read
·
Annalee Armstrong
1 of 59,845
Next
